NASDAQ: DAWNDay One Biopharmaceuticals Inc Stock
$7.14+0.30 (+4.39%)
Updated Apr 21, 2025
DAWN Price
$7.14
Fair Value Price
N/A
Market Cap
$723.67M
52 Week Low
$6.41
52 Week High
$18.07
P/E
-7x
P/B
1.44x
P/S
9.01x
PEG
N/A
Dividend Yield
N/A
Revenue
$131.16M
Earnings
-$95.50M
Gross Margin
96%
Operating Margin
-67.36%
Profit Margin
-72.8%
Debt to Equity
0.16
Operating Cash Flow
-$78M
Beta
0.74
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
DAWN Overview
Day One Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing therapies for patients with genetically defined cancers. Its lead product candidates are DAY101 and Pimasertib. Day One Biopharmaceuticals was incorporated in 2018 and is headquartered in South San Francisco, CA.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine DAWN's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
B
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
DAWN
Ranked#252 of 462
Ranked#252 of 462
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $2.55 | A | |
| $7.66 | A | |
| $22.02 | A |
Be the first to know about important DAWN news, forecast changes, insider trades & much more!
DAWN News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how DAWN scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
DAWN is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
DAWN is good value based on its book value relative to its share price (1.44x), compared to the US Biotechnology industry average (4.04x)
P/B vs Industry Valuation
DAWN is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more DAWN due diligence checks available for Premium users.
Valuation
DAWN fair value
Fair Value of DAWN stock based on Discounted Cash Flow (DCF)
Price
$7.14
Fair Value
$30.12
Undervalued by
76.30%
DAWN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
DAWN price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-7x
Industry
-184.27x
Market
27.14x
DAWN price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.44x
Industry
4.04x
DAWN is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
DAWN's financial health
Profit margin
Revenue
$29.2M
Net Income
-$65.7M
Profit Margin
-225%
DAWN's Earnings (EBIT) of -$88.35M... subscribe to Premium to read more.
Interest Coverage Financials
DAWN's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$582.8M
Liabilities
$80.0M
Debt to equity
0.16
DAWN's short-term assets ($562.33M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
DAWN's short-term assets ($562.33M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
DAWN's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
DAWN's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$30.0M
Investing
-$269.6M
Financing
$1.9M
DAWN's operating cash flow (-$78.11M)... subscribe to Premium to read more.
Debt Coverage Financials
DAWN vs Biotech Stocks
Day One Biopharmaceuticals Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.